Identifying participants' preferences for modifiable chemotherapy-induced peripheral neuropathy prevention clinical trial factors: an adaptive choice-based conjoint analysis.
Identifying participants' preferences for modifiable chemotherapy-induced peripheral neuropathy prevention clinical trial factors: an adaptive choice-based conjoint analysis.
复制标题
DOI：
10.1007/s00520-022-07447-y
复制
发表时间：
2022-12
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
没有推荐用于预防化疗诱导的周围神经病变（CIPN）的治疗方法。CIPN预防临床试验的招募具有挑战性，因为在癌症诊断和开始神经毒性化疗之间很难招募患者。这项探索性序贯混合方法研究的目的是确定患者的偏好，可能会影响选择参加CIPN预防临床试验。首先，对完成少于三次神经毒性化疗输注的成年人进行了二十次认知访谈，以澄清在决定是否参加CIPN预防试验时被认为对患者重要的临床试验属性和水平（即，治疗类型、临床试验、报销、调查交付;访视时间、随访时间、何时开始开始治疗）。其次，另外88例患者完成了适应性选择为基础的联合分析调查，纳入最终的属性和水平。每个级别被分配一个部分价值效用得分使用分层贝叶斯估计。计算每个属性的相对重要性。相对重要性值最高的属性是治疗类型（27.1%）和研究访视时间（20.2%）。首选水平包括非药物治疗（53.49%），在经历CIPN后开始治疗（60.47%），电子邮件调查63.95%）、包括调查和临床检查的评估（39.53%）、30分钟以下访视（44.19%）、每周报销50美元（39.53%）和化疗后1个月随访（32.56%）。患者的参与偏好可能会被纳入未来CIPN预防临床试验的设计中，以潜在地支持研究招募。
There are no recommended treatments for chemotherapy-induced peripheral neuropathy (CIPN) prevention. Recruitment to CIPN prevention clinical trials is challenging because it is difficult to enroll patients between the time of cancer diagnosis and the initiation of neurotoxic chemotherapy. The purpose of this exploratory-sequential mixed-methods study was to determine patients’ preferences that could affect the choice to participate in CIPN prevention clinical trials. First, twenty cognitive interviews were conducted with adults who completed less than three neurotoxic chemotherapy infusions to clarify clinical trial attributes and levels thought to be important to patients when deciding whether to enroll in CIPN prevention trials (i.e., type of treatment, clinical tests, reimbursement, survey delivery; length of visits, timing of follow-up, when to begin treatment). Second, another eighty-eight patients completed an adaptive choice-based conjoint analysis survey that incorporated the finalized attributes and levels. Each level was assigned a part-worth utility score using Hierarchical Bayes Estimation. The relative importance of each attribute was calculated. The attributes with the highest relative importance values were type of treatment (27.1%) and length of study visits (20.2%). The preferred levels included non-medicine treatment (53.49%), beginning treatment after experiencing CIPN (60.47%), email surveys (63.95%), assessments that include surveys and clinical exams (39.53%), under 30-min visits (44.19%), $50/week reimbursement (39.53%), and 1-month post-chemotherapy follow-up visits (32.56%). Patients’ preferences for participation may be included in the design of future CIPN prevention clinical trials to potentially bolster study enrollment.
登录
查看更多内容
影响因子：
28.4
作者：
Dueck AC;Mendoza TR;Mitchell SA;Reeve BB;Castro KM;Rogak LJ;Atkinson TM;Bennett AV;Denicoff AM;O'Mara AM;Li Y;Clauser SB;Bryant DM;Bearden JD 3rd;Gillis TA;Harness JK;Siegel RD;Paul DB;Cleeland CS;Schrag D;Sloan JA;Abernethy AP;Bruner DW;Minasian LM;Basch E;National Cancer Institute PRO-CTCAE Study Group
通讯作者：
National Cancer Institute PRO-CTCAE Study Group
影响因子：
4.5
作者：
Klojgaard, Mirja Elisabeth;Manniche, Claus;Sogaard, Rikke
通讯作者：
Sogaard, Rikke
影响因子：
45.3
作者：
Loprinzi, Charles L.;Lacchetti, Christina;Hershman, Dawn L.
通讯作者：
Hershman, Dawn L.
影响因子：
4.4
作者：
Muehlbacher, Axel C.;Junker, Uwe;Nuebling, Matthias
通讯作者：
Nuebling, Matthias
影响因子：
3.7
作者：
Chen, Li-Chia;Cheng, Li-Jen;Knaggs, Roger D.
通讯作者：
Knaggs, Roger D.